Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines

BMC Veterinary Research

Volumn 8, Issue , 2012, Pages

  Couto, Jason I ^a   Bear, Misty D ^a   Lin, Jiayuh ^b,c   Pennel, Michael ^a   Kulp, Samuel K ^a   Kisseberth, William C ^a   London, Cheryl A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Canine; Osteosarcoma; STAT3

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; LLL12 COMPOUND; RNA; STAT3 PROTEIN; SULFONAMIDE;

ANIMAL; ANIMAL DISEASE; APOPTOSIS; ARTICLE; BONE TUMOR; CELL PROLIFERATION; CHEMISTRY; DOG; DOG DISEASE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOG DISEASES; DOGS; OSTEOSARCOMA; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES;

MLCS; MLOWN;

EID: 84871011049     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-8-244     Document Type: Article

References (42)

1. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes & cancer 2010, 1(10):979-993. 10.1177/1947601910397187, 23447832.
2. Watson CJ, Neoh K. The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol 2008, 19(4):401-406. 10.1016/j.semcdb.2008.07.021, 18723104.
3. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9(11):798-809. 10.1038/nrc2734, 19851315.
4. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 2009, 9:81. 10.1186/1471-2407-9-81, 2666757, 19284568.
5. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One 2012, 7(2):e30820. 10.1371/journal.pone.0030820, 3271110, 22319590.
6. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research: an official journal of the American Association for Cancer Research 2002, 8(4):945-954.
7. Cimica V, Chen HC, Iyer JK, Reich NC. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One 2011, 6(5):e20188. 10.1371/journal.pone.0020188, 3098288, 21625522.
8. Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011, 20(9):1263-1275. 10.1517/13543784.2011.601739, 21751940.
9. Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv 2011, 11(1):18-26. 10.1124/mi.11.1.4, 3063716, 21441118.
10. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006, 6(3):231-241. 10.1517/14712598.6.3.231, 16503733.
11. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421. 10.1126/science.8197455, 8197455.
12. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998, 18(5):2545-2552. 110634, 9566874.
13. Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H, Duan Z. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. Journal of orthopaedic research: official publication of the Orthopaedic Research Society 2010, 28(7):971-978.
14. Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P. Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis 2012, 29(6):615-624. 10.1007/s10585-012-9475-3, 22484976.
15. Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J, Fang JY. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl) 2012, 90(9):1037-1046.
16. Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 7:111. 10.1186/1471-2407-7-111, 1964761, 17598902.
17. Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr Blood Cancer 2012, 58(3):327-333. 10.1002/pbc.23341, 21990244.
18. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer 2012, 118(18):4597-4605. 10.1002/cncr.27414, 22252521.
19. Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 2011, 11:112. 10.1186/1471-2407-11-112, 3074561, 21443800.
20. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010, 12(1):39-50. 2805882, 20072652.
21. Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2012, 30(3):916-926. 10.1007/s10637-011-9645-1, 21340507.
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3(6):1101-1108. 10.1038/nprot.2008.73, 18546601.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
24. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979, 6(2):65-70.
25. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954, 41(1/2):133-145.
26. Terpstra TJ. The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indigationes Mathematicase 1952, 14:327-333.
27. Mack GA, Wolfe DA. K-sample rank tests for umbrella alternatives. J Am Stat Assoc 1981, 76(373):175-181.
28. Juneau P. Nonparametric inference for ordered alternatives in a one-way layout using the SAS system. MWSUG Conference Procedings 2006, SD11:1-14.
29. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma Dog versus man. Clin Orthop Relat Res 1991, 270:159-168.
30. Withrow SJ, Khanna C. Bridging the gap between experimental animals and humans in osteosarcoma. Cancer Treat Res 2009, 152:439-446. 10.1007/978-1-4419-0284-9_24, 20213406.
31. Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: The Italian Sarcoma Group Experience (1983-2006). Cancer 2012, 118(20):5050-5059. 10.1002/cncr.27493, 22415578.
32. Tu B, Du L, Fan QM, Tang Z, Tang TT. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 2012, 325(1):80-88. 10.1016/j.canlet.2012.06.006, 22743617.
33. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011, 11:125. 10.1186/1471-2407-11-125, 3079692, 21481226.
34. Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer 2010, 10:187. 10.1186/1471-2407-10-187, 2874784, 20459702.
35. Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 2010, 197(1):46-53. 10.1016/j.cancergencyto.2009.10.004, 20113836.
36. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008, 283(25):17635-17651. 10.1074/jbc.M800109200, 2427357,2427357, 18441325.
37. Chen Z, Huang C, Yang YL, Ding Y, Ou-Yang HQ, Zhang YY, Xu M. Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells. Acta Pharmacol Sin 2012, 33(1):101-108. 10.1038/aps.2011.164, 22212432.
38. Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, et al. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol 2012, 83(10):1456-1464. 10.1016/j.bcp.2012.02.010, 22387047.
39. Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One 2012, 7(4):e35513. 10.1371/journal.pone.0035513, 3328460, 22530037.
40. Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, Bhasin D, Regan N, Lin L, Chan C, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 2009, 100(1):106-112. 10.1038/sj.bjc.6604793, 2634692, 19127268.
41. Lin L, Benson DM, DeAngelis S, Bakan CE, Li PK, Li C, Lin J. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer 2012, 130(6):1459-1469. 10.1002/ijc.26152, 21520044.
42. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002, 91(6):1488-1501. 10.1002/jps.10161, 12115848.